Clinical Trial Update: A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind, placebo-controlled study assessing the efficacy and safety of tesofensine (NS 2330) at 0.125, 0.25, 0.5 and 1.0 mg daily in le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Tesofensine (NS 2330) (tesofensine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED